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Zinc Nutrition and Inflammation in the Aging Retina
Rosie Gilbert,* Tunde Peto, Imre Lengyel, and Eszter Emri
Zinc is an essential nutrient for human health. It plays key roles in
maintaining protein structure and stability, serves as catalytic factor for many
enzymes, and regulates diverse fundamental cellular processes. Zinc is
important in affecting signal transduction and, in particular, in the
development and integrity of the immune system, where it affects both innate
and adaptive immune responses. The eye, especially the retina-choroid
complex, has an unusually high concentration of zinc compared to other
tissues. The highest amount of zinc is concentrated in the retinal pigment
epithelium (RPE) (RPE-choroid, 292 ± 98.5 µg g−1 dry tissue), followed by the
retina (123 ± 62.2 µg g−1 dry tissue). The interplay between zinc and
inflammation has been explored in other parts of the body but, so far, has not
been extensively researched in the eye. Several lines of evidence suggest that
ocular zinc concentration decreases with age, especially in the context of
age-related disease. Thus, a hypothesis that retinal function could be
modulated by zinc nutrition is proposed, and subsequently trialled clinically.
In this review, the distribution and the potential role of zinc in the
retina-choroid complex is outlined, especially in relation to inflammation and
immunity, and the clinical studies to date are summarized.
1. Introduction
Zinc is an essential micronutrient for all organisms, critically
required for normal cellular processes as well as for normal
metabolism.[1] The adult human contains 2–3 g of zinc, mak-
ing it the second most abundant trace element in the human
body.[2] Zinc is absorbed in the small intestine and is excreted
via the skin, in sweat, via the kidneys, in urine, and via the large
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intestine/colon, in feces. Only 0.1% of
total body zinc content is in the blood
plasma.[3] Daily intake of zinc is needed
to maintain adequate body levels: in the
United Kingdom (UK) the recommended
daily zinc intake (reference nutrient in-
take) is 9.5 mg for an adult man and
7 mg for an adult woman.[4] The Food
Standards Agency and the Department of
Health in the UK advise that intake of
zinc should not exceed 25 mg per day,
but often people take supplements of>80
mg/day.[5,6]
Approximately 60% of the total body
zinc content is found in skeletal muscle
and 30% in bone mass.[3] Of the remain-
ing organs and tissues, the eye has an un-
usually high zinc content, with the high-
est amount of zinc concentrated in the
retinal pigment epithelium (RPE) (RPE-
choroid, 292 ± 98.5 µg/g dry tissue), fol-
lowed by the retina (123± 62.2 µg g−1 dry
tissue).[7–20] Zinc exists in the other ocular
tissues, in the following (descending) or-
der of content: the ciliary body, iris, optic
nerve, sclera, cornea, and the lens.[21,22]
The neurosensory retina is a multiple layered tissue, which
lines the back of the eye and connects with the brain via the op-
tic nerve.[23] Light has to transduce the entire thickness of the
retina until it reaches the photosensitive “rod and cone” pho-
toreceptor cell layer. Blood supply to the neurosensory retina oc-
curs through retinal blood vessels, which originate from the cen-
tral retinal artery. Transport of small molecules, including pro-
teins and lipids, across retinal blood vessels is controlled by en-
dothelial tight junctions, which constitute the inner blood–retinal
barrier.[24,25] The optic nerve is composed of ganglion cell axons,
which are the “output” neurons of the retina, constituting its in-
nermost layer.[23] The retina itself is built up of three layers of
cellular bodies and two layers of synapses. In the inner nuclear
layer, there are the cell bodies of bipolar, amacrine, and horizontal
cells, while the outer nuclear layer consists of photoreceptor cell
bodies. All these cells contribute to the visual cycle, which may
be summarized as the conversion of a photochemical “message”
from visible light into a neural signal, which can be interpreted
by the brain.
Adherent junctions between rods, cones, and the photore-
ceptor inner segments create a barrier called the outer lim-
iting membrane, which separates the retina region from the
subretinal space. In the subretinal space, the RPE creates a sin-
gle monolayer. Its main function is support the maintenance of
the retina, through reducing the backscattering of light via its
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high pigment content, and removing by-products of the visual
cycle. It also prevents new vessel growth into the retinal lay-
ers from the choroidal vasculature underneath. Bruch’s mem-
brane, consisting of extracellular matrix proteins, proteoglycans
and glucosaminoglycans, separates theRPE from the choroid. To-
gether, the RPE and the Bruch membrane form the outer blood–
retinal barrier, which prevents the entrance of macromolecules
and immune cells from the underlying choroid into the pho-
toreceptor layer. Thus, the integrity of the RPE and Bruch’s
membrane are essential for maintenance of the blood–retinal
barrier and homeostasis in the retina. The choroid, located be-
low Bruch’s membrane, contains a dense network of blood ves-
sels (the choriocapillaris), which supplies oxygen and nutrients
to the RPE, outer retina and optic nerve. Unlike the endothe-
lial tight junctions of the retinal vessels, the choroid endothe-
lium is fenestrated, which enables the transport of molecules
to the metabolically demanding RPE. A simplified diagram of
the retina-choroid complex is shown in Figure 1. The choroid
contains tissue-resident melanocytes, fibroblasts, macrophages,
mast cells, and dendritic cells.[26] Muller cells, a specialized
form of local retinal glial cell, are, in contrast, found through-
out the retina. As part of the normal aging process, waste ma-
terial accumulates in the retina-RPE and RPE-choroid inter-
face. Its advanced accumulation can lead to disease, such as
age-related macular degeneration (AMD). In this review, we
summarize the distribution and known role of zinc in retina–
choroid complex, in addition to its contribution to waste material
accumulation.
Zinc is the only essential transitionmetal ion that lacks biologi-
cal redox activity. It is a Lewis acid,meaning that it acts as a proton
donor.[27] This feature makes zinc the ideal enzymatic cofactor.[28]
Zinc can either participate, directly, in chemical catalysis or, indi-
rectly, by maintaining protein structure or stability. For this rea-
son, it has an important regulatory role in a wide variety of bio-
logical processes, acting as a catalyst for more than 300 enzymes
and is contained within thousands of proteins, as a zinc finger
domain.[29–41] Zinc plays a key role in fundamental cellular pro-
cesses such as DNA synthesis, RNA transcription, cell division,
and activation,[42] as well as in prevention of cell apoptosis.[43]
It also has a significant role in affecting signal transduction for
cellular function,[44] in particular for the development and in-
tegrity of the immune system, affecting both innate and adaptive
immune responses, which represent non-specific or specific re-
sponses, respectively, to foreignmacromolecules (antigens).[37–41]
Innate immunity is characterized by physical barriers, fixed re-
ceptors based on pathogen molecular patterns, limited immuno-
logical memory, and the fact that it does not require immuniza-
tion (priming).[41] Acquired immunity is characterized by clonally
variable receptors based on gene rearrangement, development of
immunological memory, B-cell and/or T-cell activation, cytotoxic
T-cells, and antibody production.[41]
The European Food Safety Authority (EFSA) Panel 2009 re-
port states that a cause and effect relationship has been satis-
factorily established between the dietary intake of zinc and the
following biological functions: normal function of the immune
system; normal DNA synthesis and cell division; protection of
DNA, proteins and lipids from oxidative damage;maintenance of
normal bone; normal cognitive function; normal fertility and re-
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metabolism; normal vitamin A metabolism; and maintenance of
normal vision.[45] This report, however, did not conclude that that
inadequate intake of zinc, leading to impaired function of the
abovementioned health relationships, occurs in the general EU
population, based on the evidence provided to the panel.[45] In
this review, which focuses on the role of zinc in inflammation in
the aging retina, we will summarize the physiological role of zinc
in the retina (Table 1) and then discuss how zinc nutrition might
affect retinal inflammation and function, with reference to the
current literature about zinc and immunity.
2. Zinc in the Normal Retina
The retina–choroid complex contains the highest concentration
of zinc in the eye, as measured using a wide variety of techniques
in different species, including humans.[7–20]
Total cellular zinc concentration is estimated to be approxi-
mately one hundredmicromoles.[106]Themajority of intracellular
zinc is tightly bound to proteins, compartmentalized, and se-
questered with high binding affinities (in the picomolar
to femtomolar range), which allows increased cellular zinc
utilization.[74,78,103,107–115] As a consequence of this high protein-
binding affinity, the level of available zinc for biochemical
processes is maintained within a narrow concentration range[106]
and is referred to as “free,” “labile,” “readily releasable,” or
“exchangeable” zinc.[116,117] These biochemical findings rule out
that proteins with low affinity zinc binding sites might be the
physiologically relevant proteins for regulatory role of zinc.[118]
In physiological circumstances, other essential metal ions, such
as calcium, magnesium, iron, and copper can interfere with
each other, and share regulation of biological processes, hence
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Figure 1. Simplified diagram ([105]; reproduced with permission) depict-
ing the cellular organization of the retina-RPE-choroid. Total cellular zinc
concentration (left shaded bar) represents the total zinc content of the
different layers of retina-choroid complex and the grayscale bar shows the
total content relative to the each layers. The majority of total zinc is tightly
bound to proteins so that the level of exchangeable zinc, available for bio-
chemical processes, is maintained within a narrow concentration range
(right shaded bar), and the grayscale bar shows the amount of exchange-
able zinc content relative to the each layers. Cho, choroid; BM, Bruch’s
membrane; RPE, retinal pigment epithelium; OS, outer segment; IS, inner
segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner
nuclear layer; IPL, inner plexiform layer and GC, ganglion cell layer. In the
grayscale color bar, white represents the lowest concentration of zinc and
black represents the highest concentration of zinc.
these interactions should always be considered when biological
activity of zinc is being assessed.[118]
The majority of the changes in cellular zinc levels are me-
diated through 24 zinc transmembrane proteins (ten zinc ef-
flux transporters, called ZnT, and fourteen influx transporters,
called ZIP) encoded for by two solute-linked carrier (SLC) gene
families, SLC30, and SLC39, respectively.[119] These transporters
are regulated transcriptionally, translationally, and at the protein
level through heterodimer formation, ubiquitination, phospho-
rylation, and proteolysis.[120–123] Under steady state conditions, a
primary function of cytosolic zinc-binding proteins is to buffer
the relatively large zinc content found in most cells to a cytoso-
lic zinc(II) ion concentration in the picomolar range.[117] Under
non-steady state conditions, cytosolic zinc-binding proteins act
together to modulate transient changes in cytosolic zinc ion con-
centration in a process called “zinc muffling.”[117] If intracellular
zinc influx is increased, muffling reactions will dampen the re-
sulting rise in cytosolic zinc ion concentration and, eventually,
restore the cytosolic zinc ion concentration to its original value
by shuttling zinc ions into subcellular stores or by removing zinc
ions from the cell.[117] In addition, muffling reactions provide a
potential means to control changes in cytosolic zinc ion concen-
trations for purposes of cell signaling in what would otherwise be
considered a buffered environment not conducive for signaling.
The potential downstream effects of these processes are summa-
rized in Figure 2.
Metallothioneins (MTs) are zinc-ion-binding proteins[124] and
their gene expression is tightly controlled mainly by MTF-1 tran-
scription factor. Several isoforms of MTs exist and they show cell-
type specificity.[124] Zinc is bound exclusively to the sulfur donors
of cysteines in zinc-thiolate clusters.[125] One MT molecule can
bind seven zinc ions, through different binding affinities to
metals.[117,125–127] With lower zinc binding affinity, MTs react as
redox proteins. They sequester or release zinc, depending on the
local redox state, thereby trapping, not only any zinc for storage,
but also serve as zinc acceptors and donors for other proteins in a
dynamic way (zinc buffering in non-steady state conditions).[118]
Therefore, the redox inert zinc can influence the function of nu-
merous proteins, transcription factors, and enzymes.[116,117,125]
However, there are also redox modulation-independent mecha-
nisms, which seem to modulate phosphorylation signaling[128]
and zinc has a long-term effect on these gene expression levels.
MTF-1 seems to be a primary zinc sensor and induces gene ex-
pressional changes thereby, directly or indirectly, inducing other
transcriptional regulators.[129]
In order for zinc to have an effect, the bioavailable zinc level
needs to change. There are two ways that this can happen. The
first is characterized by the transport of zinc from and to the ex-
tracellular space. The second is by releasing zinc frommolecules
or intracellular stores. One of the most well studied effects of the
releasing zinc into the extracellular space is the effect on gluta-
mate receptors in neurons in the brain. The released extracellular
zinc binds and inhibits the postsynaptic N-methyl -D-aspartate
receptor[125,130] and modulates synaptic transmission. A similar
effect is observed in the neurosensory retina.[78,108]
In retinal tissue, zinc is usually stored in intracellular compart-
ments in ganglion cells, the horizontal, and amacrine cells.[78,108]
Zinc localization in retinal Muller cells has also been demon-
strated in previous studies. Depolarization of the retinal neurons
can induce zinc release at the plexiform layers,[74] which provided
the first evidence for the hypothesized neuro modulator role for
zinc in the retina.[68,131,132] Endogenous zinc is co-released with
glutamate from synaptic terminals of photoreceptors and, by neg-
ative feedback, reduces calcium entry and concomitant vesicular
release of glutamate.[81,83] This is, therefore, likely to protect the
retina from glutamate excitotoxicity.[83]
Zinc can be released from the cellular compartments or stores
by molecules such as MTs, by external stimuli. Amongst the
many roles of zinc in intracellular processes, zinc release can
lead to the activation and phosphorylation of the MAPK/ERK
pathway[133] and/or zinc transporters.[134] Intracellular increase in
free zinc can generate effects in seconds, called “zinc sparks,”
or in minutes, called “zinc waves.”[117] The downstream molec-
ular events are not yet well characterized.[135] Therefore, the di-
rect molecular events determining zinc stimuli and acceptance
of zinc, as a second messenger, need further investigation.[118]
In addition to its presence in organelles, intracellular zinc
is present in the outer segments of photoreceptors,[103,110–112]
where the availability of zinc is dependent on light-dark adap-
tation. In fact, zinc is required for the stabilization of disc
membranes in the outer segments,[136] probably through the
stabilization of rhodopsin.[17] However, additional low affinity
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Table 1. Summary of studies providing evidence for the physiological role of zinc in the retina.
Cell type Zinc study focus/main finding Reference
Developing retina Role of Zic family of zinc finger transcription factors in early retinal progenitor cells in mouse
retina
[46]
Relative axial myopia in Egr-1 (ZENK) -/- KO mice [47]
Role of Zic-3 in intra-retinal axon projection in chicken [48]
Zic-2 regulates retinal ganglion cell axon repulsion in mice [49]
Mutation in ZNF644 associates with high myopia [50]
ZIC408 in retinal vasculogenesis in zebrafish [51]
Spalt in cone photoreceptor and retinal horizontal cell development in mice [52]
ZIP4 knockout mice, exencephalia, severe growth retardation, and hydrocephaly, was
accompanied by unilateral or bilateral anophthalmia.
[53]
Zip13 knockout caused sunken eyes which were also associated with down slanting palpebral
fissures
[54]
Adult retina Zinc deficiency in retinitis pigmentosa [55]
Improved dark adaptation in liver cirrhosis upon zinc supplementation [56]
Adequate dietary zinc is protective against AMD [57–62]
Inhibition of complement activation in AMD upon zinc supplementation [63]
Reduced zinc level in retina with aging and in AMD in vivo [18,20]
Stimulatory effect of Zn on ERG b wave amplitude in vertebrate retina [64–68]
Retinal gene expressional changes upon zinc-deficient/sufficient diet in rat retina [69,70]
Horizontal and
bipolar cells
Role of extracellular zinc in regulation of AMPA mediates postsynaptic signals in skate
horizontal cells and bipolar cells.
[70–72]
Inhibition of extracellular zinc on hemi-gap-junction channel currents on retinal horizontal cells
in bass
[73]
Zinc release by depolarization of retinal cells in rat [74]
Modulation of A-type potassium currents by zinc in retinal horizontal cells [75]
Amacrine cells Differential modulation of signal from cones to horizontal cells by extracellular zinc [76]
Zn(2+) modulates light responses of bipolar and amacrine cells in carp retina [77]
Modulatory role of endogenous zinc upon glycinergic response in amacrine cells in rat retina [78]
Suppression by zinc of transient OFF responses of carp amacrine cells on GABA receptors [79]
Photoreceptors Synaptically released zinc from rod photoreceptors in zebrafish [80]
Modulatory role of extracellular zinc upon calcium activity the photoreceptor terminal [81]
Role of Yin Yang 1 in melatoninergic function of retinal photoreceptors. [82]
Zinc co-release with glutamate by photoreceptors; cytoprotective role in skate retina [81,83]
Translocation of zinc within photoreceptors in light stimulation [17]
Stabilization of disc membranes in bovine and mice retina and in vitro model modelling [84–88]
Role of KLF15 in repression of photoreceptor-specific gene expression in non-photoreceptor
cells in vitro molecular model system
[89]
RPE Zinc decrease in RPE layer in disease in vitro [9]
Regulatory role of melanin synthesis and melanosome formation in RPE cells in vitro and in
vivo in rats
[90–92]
Protective role of zinc against oxidative stress in vitro RPE [32,93,94]
Role of zinc in phagocytic and lysosomal activity in vitro RPE [95–98]
Role of zinc in apoptosis in in vitro RPE [99]
Protective role of zinc against UV-induced DNA damage in vitro RPE [100]
Enhanced pigmentation upon zinc supplementation in vitro [101]
Role of snail zinc finger transcription factor in epithelial mesechymal transition of human
ARPE-19 retinal pigment epithelial cells
[102]
Sub-RPE space High content of zinc in sub-RPE waste material [103]
Choroid Blockade of choroidal endothelial cell migration in response to AREDS formula zinc [104]
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Figure 2. Schematic diagram depicting how zinc buffering/ muffling and involvement of high zinc binding affinity proteins can maintain steady state
conditions, with a variety of downstream effects, whichmay ultimately influence immune function. Intracellular zinc levels are tightly controlled. Cytosolic
zinc-binding proteins buffer the relatively large zinc content, found in most cells, to a cytosolic zinc(II) ion concentration in the picomolar range, and also
act together to modulate transient changes in cytosolic zinc ion concentration in a process called “zinc muffling.” If intracellular zinc influx is increased,
muffling reactions will dampen the resulting rise in cytosolic zinc ion concentration and restore the cytosolic zinc ion concentration to its original value
by shuttling zinc ions into subcellular stores or by removing zinc ions from the cell. The potential downstream events can be immediate/short term (for
example, a change in enzyme activation) and long-term effects (for example, a gene/protein/secretional change). All of these can lead to changes in
immune function, however the mechanism for this is yet to be elucidated in the retina-choroid complex.
zinc binding to specific histidine sites can also lead to de-
stabilization of rhodopsin,[86] and decreased thermal stability,[87]
suggesting that rhodopsin might be less stable in light than
in dark. This zinc-induced de-stabilization of rhodopsin might
be especially relevant in inherited genetic retinal diseases,
such as retinitis pigmentosa, which is associated with the
Pro23His mutation,[86] further supporting zinc-induced instabil-
ity of rhodopsin.[86] It is of note that retinitis pigmentosa is associ-
ated with systemic zinc deficiency.[55] Outer segment zinc content
can also affect the conversion of vitamin A (retinol) to retinal[137]
by the zinc-dependent alcohol dehydrogenase[138,139] and this can
be clinically manipulated by zinc supplementation.[140] Zinc may
also be involved in dark adaptation by affecting the synthesis or
release of retinol-binding proteins in the liver.[141] Where and how
this reported increase in total zinc in the outer segment[17] origi-
nates from is an important factor, which is still to be determined.
Zinc is abundantly enriched in the sub-retinal space,[142] espe-
cially in sub-RPE deposits.[143] The increased levels of zinc found
in the sub-RPE space could be explained by the dysfunction of
zinc-rich RPE, occurring in disease states. Indeed, elemental dis-
tribution of Zn showed preferential decrease of zinc in the RPE
layer in disease.[9] Zinc content and retention is mediated, at least
partly, by pigmentation of the RPE,[9] as melanin synthesis and
melanosome formation appears to be regulated by zinc.[92] The
RPE is also rich in exchangeable zinc[144] localized to the Golgi
apparatus,[108] melanosomes and lysosomes.[14,91,108–110,112,145–149]
The macula RPE may contain less zinc than the peripheral reti-
nal RPE, and it is thought that macula zinc levels may be fur-
ther affected by aging.[150] Bruch’s membrane contains a sub-
stantial amount of zinc, especially in eyes with AMD (which is
discussed in more detail in a later section).[103] As some of this
zinc is in the exchangeable form,[103] it is possible that there
is an extracellular zinc milieu that requires active control for
the regulation of extracellular proteins, involved in the immune
response,[151] or for the remodeling of the extracellular matrix by
metalloproteinases.[152]
The highest concentration of zinc in the eye has been lo-
calized to the choroid.[18,19] Since the choroid is a highly pig-
mented layer, it is likely that pigmentary zinc contributes to
this enrichment. It is worth noting that the immunohistologi-
cal features of two well recognized uveitis syndromes with sim-
ilar phenotypes: Vogt-Koganagi Harada syndrome and sympa-
thetic ophthalmia, characterized by choroidal inflammation and
serous retinal detachments, support a delayed type of hypersen-
sitivity (T-cell-mediated) mechanism directed towards the uveal
melanocytes of the choroid, which is inducing and/or perpetu-
ating an autoimmune-type chorioretinal inflammation.[153,154] In
combination with the evidence linking zinc and choroidal pig-
ment, this hints at a possible relationship between zinc, choroidal
pigment, and chorioretinal inflammation, where accumulation
of zinc and exposure of antigens derived from choroidal pigment,
as a result of RPE dysfunction in AMD, could be contributing to
retinal inflammation. However, at the present time, relatively lit-
tle is known about the role and function of zinc in the choroid,
and its relationship to inflammation, other than that zinc appears
to accumulate with increasing age[18] and that it may contribute
to the developing zinc deficiency in the inner layers of an aged
eye.[20] What we do know about the relationships between zinc,
inflammation, and immunity, which may be of relevance to reti-
nal inflammation, is summarized in later sections.
3. Suboptimal Dietary Zinc Status and Deficiency:
Clinical Manifestations
An adequate daily intake of zinc is necessary to achieve a steady
state for proper immune function, because there is no special-
ized zinc storage system in the human body. Therefore, zinc
deficiency often occurs because of malnutrition, especially in
the elderly.[155,156] Physiologic effects of systemic zinc deficiency
are associated with a number of diverse biochemical and im-
munological changes in the human body.[157] Notably, a clinical
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syndrome suspected to be secondary to zinc deficiency was first
reported from Iran in 1961, consisting of wide range of deficits in-
cluding growth retardation, male hypogonadism, skin changes,
mental lethargy, hepatosplenomegaly, iron deficiency anemia,
and geophagia.[158] Subsequent interest concerning the effect of
zinc deficiency on visual function came from the observation that
abnormal visual dark adaptation in patients with alcoholic liver
disease (cirrhosis) was improved by zinc supplementation.[140]
The mechanism for this could be the effect of zinc on the syn-
thesis or release of retinol-binding proteins in the liver.[141] Sim-
ilar clinical observations regarding zinc and dark adaption were
made in a case series of sickle cell anemia patients,[159] and also
healthy human subjects,[160] which suggested that these effects
on visual functionmay be related to dietary zinc deficiency. Since
then, an increasing amount of research has shown that diet in-
fluences local retinal zinc homeostasis. Zinc supplementation re-
sults in a higher amount of intracellular retinal zinc,[161] whilst a
zinc-deficient diet induces retinal gene expressional changes.[69]
Light-induced retinal degeneration and visual cell loss in rats re-
sulted in gene expressional changes (attributed to inflammation,
apoptosis, cytokines, the innate immune response, and related
receptors) and this type of induced retinal degenerative change
was shown to decrease in response to the addition of a zinc ox-
ide, plus rosemary, antioxidant mixture.[70] As described earlier,
zinc-induced de-stabilization of rhodopsin might be relevant in
inherited genetic retinal diseases such as retinitis pigmentosa,[88]
which is also associated with systemic zinc deficiency.[55] Also,
the conversion of vitamin A (retinol) to retinal[137] by the zinc-
dependent alcohol dehydrogenase[138,139] may be clinicallymanip-
ulated by zinc supplementation.[140]
Worldwide, zinc deficiency in human subjects has since been
reported to occur in physiological conditions where there is an
increased requirement for zinc, for example, during childhood
and pregnancy,[162] and it was originally observed that these defi-
ciencies occurred in countries where primarily cereal proteins are
consumed by the population.[1] Although, in both industrialized
and developing countries, theremay be inadequate dietary intake
of zinc, inhibitors of zinc absorption are most likely the most
common causative factor in zinc deficiency.[163] Phytate, which
is present in staple carbohydrate-based foods, such as cereals,
corn, and rice, is now known to have a strong negative effect on
zinc absorption from composite meals.[163] Thus, zinc deficiency
is believed to occur on a spectrum, in any given population,
ranging from severe cases to marginally deficiency and subopti-
mal status[1,163] and may be secondary to both dietary intake and
absorption.
4. The Aging Retina: Age-Related Macular
Degeneration (AMD)
In developed countries, up to 30% of elderly people are zinc-
deficient and it has recognized that zinc may have an important
role in degenerative disorders of aging, as a regulator of the an-
tioxidant pathway and as an anti-inflammatory agent.[70,164] Aging
of the retina, specifically, the central retinal macula area of the
eye, is considered one of the most important clinical problems
affecting vision. In particular, AMD affects about one quarter of
people over the age of 65 years[165] and late stage disease accounts
Figure 3. Clinical retinal fundus photograph of the right eye macula show-
ing the soft, large, confluent yellow drusen (sub-RPE deposits), which are
characteristic of high risk AMD.
for approximately 50% of legal blindness in Europe and North
America.[166,167]
A key feature of AMD is the presence of extra-cellular deposits
between the choroid and the RPE.[168] These deposits vary in size
and have been classified in a number of different ways.[169–173]
Clinically, the term drusen is used to monitor progression of vi-
sual loss, as the other types of deposits are not readily visualized.
Small drusen may not always be associated with risk of visual
loss. However, multiple large drusen, located in the macular re-
gion, increases the risk of AMD (Figure 3). Drusen accumulation
occurs naturally with age and an individual druse has the capacity
to distort and rupture through the RPE and pushing into the neu-
ral retina.[172] Hence, development and progression of sub-RPE
deposit formation are likely to be a key factor in AMD pathogen-
esis. Understanding how such deposits are formed is key to elu-
cidating the mechanistic basis of this disabling eye condition.[151]
The composition of sub-RPE deposits, the so-called drusen, is
complex.[174,175] In addition to proteins and lipids, drusen contain
anomalous deposits of zinc, some of which is in the exchangeable
(ionic or loosely protein bound) form.[103] However, the origin of
the millimolar zinc in the Bruch’s membrane, which is the extra-
cellular matrix in which the sub-RPE deposits are formed, is still
not clear.
The “dry” form of AMD can be classified into early, interme-
diate, and advanced stages.[176–178] In the early stages, extracellu-
lar deposits start to accumulate at the apical and basal side of
the RPE. As the disease progresses, the size of the drusen in-
creases, to more than 125 µm in diameter, and RPE pigmentary
abnormalities appear. The etiology of dry AMD is not well un-
derstood but in geographic atrophy, the end stage of dry AMD,
it is known that the RPE cells slowly degenerate and may at-
rophy completely—a progression that takes many years before
advanced vision loss develops. In addition to the geographic at-
rophy of dry AMD, the other common clinical variant of late
stage AMD, is an aggressive “wet” form, in which the integrity of
Bruch’s membrane is broken, and rapidly progressive choroidal
neovascularization (CNV) and vision loss develops. Neovascu-
lar wet AMD can be treated with some success with intravitreal
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anti-VEGF injections[179] but there is currently no treatment for
dry AMD.
In vitro studies of RPE cells have validated that there is a de-
crease in endogenous zinc levels with increasing age, and that
the basolaterally localized ZIP2 and ZIP4 is reduced as a func-
tion of RPE age.[180] As is the case with other cells and tissues,
the RPE can be damaged by too much or too little zinc.[99,181]
Newsome et al. demonstrated that levels of zinc are reduced
in human eyes with signs of AMD.[182] This was proposed to
lead to increased oxidative stress,[32,93,94] deficits in phagocytic
and lysosomal functions,[95,97,98] macromolecule synthesis- and
caspase-dependent apoptosis,[99] increased photic injury,[165] and
UV-induced DNA damage[100] in the RPE. As described earlier,
light-induced retinal degeneration and visual cell loss in rats re-
sults in gene expressional changes related to inflammation, apop-
tosis, cytokine production, and innate immune responses; and
these pathways can be suppressed by zinc supplementation, in
combination with Age-Related Eye Disease Study (AREDS) an-
tioxidant supplement formula and other antioxidants.[70] Further-
more, the effect of AREDS formula plus zinc has been inves-
tigated on mouse choroidal endothelial cells, demonstrating a
blockage of endothelial cell migration and a decrease in the num-
ber of macrophages bound to endothelial cells.[104]
This short and, no doubt, incomplete list shows that changes
that the zinc in RPE may potentially play a multitude of roles in
the development of AMD. However, it does not provide an an-
swer to the question of from where the millimolar zinc levels of
zinc in the Bruch’s membrane are derived. However, it is known
that the RPE has very high concentrations of intracellular total
zinc (see Figure 1). In addition, one of the RPE’s functions is
the phagocytosis and processing of the zinc-rich photoreceptor
outer segments, potentially enriching the RPE zinc content fur-
ther. As RPE damage is thought to be the precursor for the de-
velopment and progression of AMD,[165] abnormal zinc release
fromRPEmay occur as the consequence the damage highlighted
above. The choroid is also rich in zinc and changes associated
with AMD here[183] may also contribute to the accumulation of
zinc in the Bruch’s membrane. These suggest that buffering zinc
in the Bruch’s membrane could be important in mediating sub-
RPE deposit formation and hence the development of AMD.
5. Clinical Studies of Zinc and AMD
A single center study of a randomized controlled trial of daily
dose of zinc sulfate (100mg) versus placebo, showed a signif-
icantly positive treatment effect on visual acuity change com-
pared to baseline, with a decreased likelihood of final visual
acuity deterioration.[57] Thus, the idea that restoring zinc bal-
ance through diet or supplementation may protect against AMD
provides an interesting and potentially inexpensive intervention
strategy and subsequent clinical trials have attempted refine
this concept.[58] Evidence from the large randomized, placebo-
controlled AREDS clinical trials, which initially evaluated high-
dose supplementation with vitamins C and E, beta carotene, with
or without zinc (zinc oxide 80 mg) and copper,[59] and later added
xanthophyll carotenoids, lutein, and zeaxanthin with or without
omega-3 fatty acids supplementation in AREDS 2, suggested that
these components may help protect against the progression to
AMD and related vision loss.[5,35,36,184] In particular, it has been
shown that retinal degenerative pathways are suppressed by zinc
supplementation, in combination with the AREDS formula and
other antioxidants.[70] In parallel with AREDS, the Rotterdam Eye
Study, a population-based cohort study, suggested that zinc sta-
tus, above median intake of vitamins E, C, and beta-carotene,
was associated with a 35% reduced risk of incident AMD.[60] This
was further supported by analyses from the Blue Mountains Eye
Study, which found that higher dietary zinc intake had a favorable
effect on incident AMD.[61,62]
The effect of zinc supplementationmay be determined accord-
ing to genetic background. In the Rotterdam study population,
zinc nutritionwas beneficial for patients with early AMDcarrying
high complement factor H gene (CFH) genetic risk variant.[185]
Patients from AREDS study carrying exclusively age-related mac-
ulopathy sensitivity 2 (ARMS2) risk alleles, and not CFH, derived
maximum benefit from zinc-containing AREDS formula[186,187]
(although others found errors in the data used to support the
initial claim of genotype-treatment interaction[188]). It is still not
known at which stage of disease the protective effects of zincmay
be important, or when the potential negative interactions with ge-
netic and/or other risk factors become significant. Furthermore,
there have been some conflicting results amongst zinc supple-
mentation trials and epidemiological studies.[189–193] Therefore,
the role of zinc in the pathogenesis of AMD needs to be further
investigated.
6. Zinc and Complement in AMD
Dysregulation of the innate immune system can lead to autolo-
gous tissue damage and development of degenerative diseases.
Complement has been recently recognized as a key player of
the innate immune system, which, in addition to defending the
host against pathogen infection, also coordinates various events
during inflammation, and bridges innate and adaptive immune
responses.[194] There are three complement pathways: the classic
pathway, the lectin pathway, and the alternative pathway.[194] All
three pathways converge at the formation of the C3 convertase,
which cleaves C3, and triggers a cascade of events leading to the
formation of a membrane attack complex (MAC), which destroys
pathogens or damaged “self” cells, by opsonisation and/or lytic
destruction.[194]
Since the identification that the CFH polymorphism (in a re-
gion known to bind heparin and C-reactive protein) was found
to be strongly associated with AMD,[195] the complement com-
ponent of innate immunity has been heavily implicated in the
pathogenesis of AMD.[196] Several studies have found evidence
of deposition of complement proteins in drusen, a focus of in-
flammatory activity, including complement components C3a and
C5a,[197] C5 and C5b-9 terminal complement complex (TCC),[198]
in addition to fluid-phase complement regulators (comple-
ment factor H-CFH, vitronectin, and clusterin) and membrane-
bound complement inhibitors (complement receptor 1-CR1, also
called CD35, and membrane cofactor protein-MCP, also called
CD46).[199,200] Notably, CFH binding to mononuclear phagocytes
was shown to curb the CD47-mediated elimination of resident
immune cells in a murine retinal model system.[201] Thus the
presence of mutant CFH may inhibit CD47-mediated resolution
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of retinal inflammation, driven by residentmacrophages and dis-
rupt homeostasis in the subretinal space. CFH, and its Tyr402
mutant form, is possibly of most interest in relation to zinc, sub-
RPE deposit formation and AMD.[202–206] It was shown, almost
30 years ago, that millimolar concentrations of zinc induced the
oligomerization of CFH and rendered it inactive in experimental
“test tube” conditions.[207,208] Later, it was found that there was no
need for millimolar extracellular zinc levels to trigger oligomer-
ization and inhibition of CFH. Large oligomers were formed in
the test tube at levels higher than 20 µm zinc, and at zinc levels of
200 µm, more than 85% of CFH is oligomeric and in its fully in-
hibited form.[151]Therefore, we hypothesize that similar oligomer-
ization occur in the Bruch’s membrane, in AMD. It has been
shown that inactivation of CFH and the uncontrolled activation
of the alternative pathway, resulting in secondary C3 deficiency,
is part of the pathological process leading to AMD.[209] In addi-
tion, Hageman et al.[203] provided evidence that CFH, together
withC3b/iC3b, membrane attack complex, and C5b-9, are con-
stituents of sub-RPE deposits. Therefore, the potential to release
exceptionally high levels of zinc from the RPE, through injury to
this cell layer, and the fact that the Bruch’s membrane contains
high concentrations of zinc in AMD,[103] suggests that zinc could
potentially induce the kind of pathological protein aggregation
described above.[151,210,211] As oligomerized CFH will have atten-
uated complement inhibitor function, the RPE and the choroid
will be at sustained risk for alternative pathway-mediated com-
plement attack. Within the complement system, zinc may affect
more than just CFH. Zinc may bind to a number of complement
proteins[212] and affect complement activity in several different
ways.[213–216] In summary, these data seem to support the proposal
that complement-mediated inflammation is a major pathological
driver of AMD.[203] Whether the Tyr402His mutation will serve
as an additional zinc binding site requires more experimental
proof.
7. Zinc as Modulator of Humoral and Cellular
Immunity: Implications for Inflammation in the
Retina
In addition to its impact on several biological processes discussed
earlier, zinc can function as an anti-inflammatory agent. Zinc is
essential for the development and maintenance of both the in-
nate and adaptive compartments of the immune system and,
therefore, has a key role in the modulation of inflammation.
Aging is known to affect immune function in the older pop-
ulation, mainly adaptive immunity characterized by the T cell-
mediated immune response,[217] and these changes have been
termed “immunosenescence.” Immunosenescence may lead to
immune dysregulation, which can result in an increased produc-
tion of pro-inflammatory cytokines, a status known as “inflamm-
aging.”[218] With regard to cellular immunity, both zinc deficiency
and supplementation have important effects on the develop-
ment and function of T cells, B cells, NK cells, monocytes, and
macrophages.[218] Rapid as well as delayed changes in readily ex-
changeable zinc (free Zn) and the zinc proteome are crucial in
determining activation of immune cells, cytokine responses, sig-
naling, and nutritional immunity.[219] In particular, age-related ef-
fects on T-cell cytokine signaling and T-cell activation induced
cell death have been observed, which may be modulated in vitro
by zinc.[220]
As mentioned previously, mild zinc deficiency is common in
older people and is characterized by a decline of serum or plasma
zinc levels with age.[218] Zinc supplementation studies in the el-
derly suggest that replacing the zinc deficit in this population re-
sults in decreased incidence of infections and decreased genera-
tion of inflammatory cytokines.[164] A studywhich determined the
effects of zinc deficiency and age on the induction of inflamma-
tory responses, using an in vitro cell culture system and an aged
mouse model showed that zinc deficiency, particularly the reduc-
tion in intracellular zinc in immune cells, was associated with in-
creased inflammation with age.[221] Furthermore, it was demon-
strated that reduced Zip 6 zinc transporter expression enhanced
proinflammatory response, and age-specific Zip 6 dysregulation
correlated with an increase in Zip 6 promoter methylation.[221] Fi-
nally, this study showed that restoring zinc status, via dietary sup-
plementation, reduced aged-associated inflammation.[221] These
data suggest that cellular zinc levels, which may be subject to
epigenetic regulation, contribute to increased susceptibility to in-
flammation with age and that dietary zinc supplements may help
to counteract these effects in zinc-deficient older people.
It is well known that almost all age-related degenerative dis-
eases involve chronic inflammation, including those that occur in
immune-privileged tissues, such as the retina and the brain.[222]
Ocular immune privilege may be described as: “a complex phe-
nomenon that involves multiple components, starting with se-
questration behind an efficient blood–retina barrier, through ac-
tive local inhibition by soluble and surface-bound molecules that
actively inhibit activation and function of adaptive and innate im-
mune cells, and culminating in systemic regulation via induction
of T regulatory cells.”[223] Failure of ocular immunological toler-
ance may lead to classical autoimmune-type inflammation, man-
ifesting as inflammatory disease of uvea (uveitis). Inflammation
of the choroid, the posterior section of the uvea, is often associ-
ated with inflammation of the overlying retina.
T-helper (Th)1 and Th17 subsets, characterized by expression
of T-bet (Tbx21) and retinoic-acid related orphan receptor (ROR)
γ -t (Rorc) transcription factors and secretion of the “signature”
pro-inflammatory cytokines, interferon (IFN)-γ and IL-17, re-
spectively, are thought to be causal agents in the pathogenesis of
autoimmunity.[224,225] Th17 effector cells may be induced in par-
allel to Th1, and, like Th1, polarized Th17 cells have the capacity
to cause inflammation and autoimmune disease.[225] The Th2 ef-
fector subset, characterized by the transcription factor, GATA-3,
and production of cytokines IL-4, IL-5, and IL-13, was initially de-
scribed around the same time as the Th1 subset,[226] and before
the Th17 subset was discovered. Although both Th1 and Th2 have
important roles in host defense (with Th2 being particularly im-
portant in allergic responses and the clearance of extracellular
pathogens), only the Th1 subset has been widely implicated in
autoimmune inflammation.[225,226]
Thymic-derived and peripherally-induced “regulatory” T-cells
(Treg) are an important physiological immune mechanism to
suppress autoreactive T-cells and other sources of endoge-
nous inflammation. The identification of the Forkhead fam-
ily transcription factor, (Fox)P3[227,228] and its specific expres-
sion in CD4+CD25+ T cells, a specialized subset of T-cells with
Mol. Nutr. Food Res. 2019, 63, 1801049 1801049 (8 of 16) C© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.advancedsciencenews.com www.mnf-journal.com
Figure 4. Cartoon representation of the FOXP3 protein, which contains a large (181 aa) amino-terminal repressor domain region, required for tran-
scriptional activation and repression, a central C2H2 zinc-finger domain, to which no specific function has yet been ascribed, a leucine-zipper domain
implicated in multimer formation and suppressor function, and a C-terminal forkhead (FKH) domain that mediates DNA-binding by FOX proteins.
FOXP3 is preferentially expressed in T regulatory (Treg) cells and is critical for their immunosuppressive function.
Figure 5. Cross-sectional histological specimens of murine retina ([241]; reproduced with permission), demonstrating the anatomical cellular organi-
zation of the retina/RPE/choroid complex as previously shown in Figure 1. Figure 5a shows normal murine retina with organized anatomical cellular
layers, whereas Figure 5b depicts inflamed retina from a murine model of EAU, demonstrating dark pink subretinal deposits/infiltrate originating in the
choroid layer, with disruption of the RPE layer and overall disorganization of retinal anatomical layers.
capacity to suppress inflammation,[229] has defined FoxP3 expres-
sion as a key phenotypic marker of Treg. These phenotypically
categorized CD4+CD25+FoxP3+ Treg suppresses inflammation
through direct cell-to-cell interactions and anti-inflammatory cy-
tokine production, such as IL-10 and transforming growth fac-
tor β (TGF-β), in addition to other mechanisms.[224,230–233] FoxP3
is considered the Treg “master transcription factor” because it
is critically required for Treg-cell development and function,
and for suppressing autoimmunity.[229,234–236] The FoxP3 protein
contains a forkhead (FKH) domain at the C terminus, critical
for nuclear localization and DNA binding, an N terminus tran-
scriptional repressor domain, in addition to C2H2 zinc finger
and leucine zipper domains, which mediate DNA binding and
dimerization (Figure 4).[237] Interestingly, electrophoretic mobil-
ity shift assay (EMSA) experiments have confirmed that both
the DNA-binding FKH domain and an intact leucine-zipper do-
main, which mediates homo-multimerization of FOXP3, are re-
quired for DNA binding, whereas the zinc-finger domain is
dispensable.[238,239] Thus, the molecular basis by which the zinc
finger domainmight influence FOXP3- regulated gene transcrip-
tion and Treg suppressive function (if indeed it does) is still to be
elucidated.
Much of our knowledge of the pathogenesis of human chorio-
retinal inflammation has derived from animal models. Experi-
mental autoimmune uveitis (EAU) is induced by immunizing an-
imals, most commonly, rodents, with a retinal antigen (Ag), such
as interphotoreceptor retinoid binding protein (IRBP) or retinal
soluble Ag (S-Ag)[233,240] (Figure 5).
These retinal Ags are involved in the visual cycle and are typ-
ically unique to the eye, therefore serving as targets for the im-
mune system in EAU. The blood–retinal barrier can be an effec-
tive barrier to small molecules but it is not a very effective barrier
to cells. For example, circulating IFN-γ producing Th1 cells and
monocytes, which have been activated systemically, are able to
cross the blood vessels and penetrate the barrier in the context
of inflammation.[242,243] When previously “unknown” retinal Ag
are exposed to the immune system, a break in immune tolerance
may occur and then an inflammatory response ensues.
Inflammation in EAU has been shown to be mediated by
the Th1 and Th17 T-cell subsets and may be suppressed by
Treg.[224,225,230–233] A study in rats found that during resolution
of the first acute attack of EAU, the number of ocular Tregs
increased.[244] Interestingly, the suppressor function of Tregs was
weaker in those rats who went on to develop recurrent EAU.[244]
In mouse models of EAU, a significantly increased frequency
and immunoregulatory action of Treg cells has been associated
with the development and regression of EAU, suggesting that
CD4+CD25+ Treg cells are induced during EAU and may be in-
volved in its regression.[245] This is further supported by murine
EAU evidence demonstrating that retina-specific functionally
suppressive FoxP3+ Tregs accumulated in inflamed eyes and per-
sisted for several months after disease remission.[246] Depletion
of Tregs at the peak of uveitis delayed resolution and, following
resolution, (when mice displayed a low grade chronic inflamma-
tion), Treg depletion precipitated disease relapse.[246] One mech-
anism by which zinc has been shown to influence levels of T-
cellmediated inflammation is by inducing a tolerogenic dendritic
cell phenotype (characterized by diminishing surface MHC class
II (MHCII) and promoting programmed death–ligand (PD-L)1,
PD-L2, and the tryptophan degrading enzyme, IDO), which in
turn skews the Treg cell–Th17 balance against inflammation.[247]
Zinc supplementation has also been found to augment T-reg in-
duction through upregulation of FoxP3[248] and TGF-β depen-
dent mechanisms.[248] Interestingly, in a murine model of exper-
imental automimmune encephalitis (EAE), zinc administration
diminished EAE scores in vivo, reduced Th17 RORγT+ cells and
significantly increased inducible Treg cells.[249] Thus, it was sug-
gested that zinc supplementation was capable of inducing tol-
erance in unwanted immune reactions by increasing Treg cell
activity, and zinc has been proposed as a promising future tool
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for treating autoimmune inflammation, without suppressing the
whole immune system.[249]
Despite an increased understanding of metabolic and phys-
iologic changes that occur in the retina with age, we still do
not know the exact immunological changes that cause or drive
AMD progression. In particular, there is a paucity of evidence
to suggest that T-cells are a major driver or regulator of chronic
inflammation in AMD. “Para-inflammation” first described by
Medzhitov, and summarized as “a tissue adaptive response to
noxious stress or malfunction and has characteristics that are
intermediate between basal and inflammatory states,”[250] how-
ever, has been proposed as a mechanism for AMD pathogen-
esis in the retina. In the aging eye, and especially at the level
of the RPE, there is an accumulation of the products of oxida-
tive stress, such as reactive oxygen species (ROS), which fur-
ther drive oxidative stress, and potentially alter the metabolism
and health of the RPE.[251,252] Sources of ROS may be physio-
logical, for example, from the accumulation of lipofuscein flu-
orophore A2E, a by-product of the visual cycle generated from
the phagocytosis of photoreceptor outer segments, or environ-
mental sources of photo-oxidative stress unique to the eye, that
is, UV light exposure, in addition to modifiable factors such as
cigarette smoking and high dietary fat ingestion, which promote
pathological inflammatory activity in response to oxidative stress
in the retina.[253] Tissue-resident immune cells and supporting
stromal cells, such as the RPE and microglial in the retina and
choroid, are capable of controlling as well as mounting immune
responses, and it is thought likely that these cells may be act-
ing as key mediators of inflammation in the aging retina.[252]
Macrophages and dendritic cells are not normally present in the
retina, but reside in the underlying choroid. As in the case of
uveitis, where there is a breakdown of the blood–retinal barrier,
these immune cells are recruited from the underlying choroid or
from the systemic circulation into the retina where they modu-
late disease.[26] Subretinal migration of microglia is necessary to
eliminate visual by-products and tomaintain vision, and their im-
paired migration into or out of the subretinal space promotes the
death of photoreceptor cells.[26] Thus, oxidative damage may be
an initial trigger for AMD and this increased physiological stress
could activate the resident immune cells to further contribute to
cell and tissue damage, with resultant loss of function.[254] Ox-
idative stress should be counterbalanced by mechanisms that at-
tempt to return the cell to a homeostatic state. Microglia may ac-
cumulate in the subretinal space as a symptom of inflammatory
damage and a beneficial response to injury, but, in AMD, this ac-
cumulation of cells andmetabolic waste products in the sub-RPE
space exacerbates progression of age-related degeneration.[26]
Macrophages, in particular, seem to play an important role in
AMD pathogenesis.[194,255] In striking similarity to their presence
at atherosclerotic blood vessel sites in cardiovascular disease,
macrophages are found at the sites of RPE atrophy, breakdown of
Bruch’s membrane, and choroidal neovascularization.[194,256,257]
With the accumulation of cell damage and oxidative stress in
the aging retina, macrophagesmay become overburdened,much
like the overload of lipids in foam cells in atherosclerosis, and
furthermore, the macrophage itself is undergoing aging and
loss of phagocytic capacity.[194] Contrary to the observed shift of
macrophages from the prototypic pro-inflammatory M1 pheno-
type (which engulf and digest damaged cells and produce proin-
flammatory factors and generate ROS) to the prototypic M2 anti-
inflammatory phenotype, usually associated with aging, in AMD
patients, this shift is reversed.[194,258] In AMD, there is an in-
crease in number of choroidal macrophages, which express com-
plement receptor CRIg.[259] Since an important function of the
complement cascade is to coat self and foreign particles with
C3-proteins that serve as ligands for phagocytic receptors (op-
sonisation), this may reflect an attempt to clear an increased
number of damaged or apoptotic cells in the aging retina, using
macrophages and the complement system.[260] It is known that
deficits in zinc adversely impact macrophage function, resulting
in dysregulation of phagocytosis and cytokine production,[261] and
this supports that local availability of zinc may influence levels of
retinal inflammation, driven by resident immune cells. With re-
gard to specific cellular interactions of macrophages with zinc,
it has been observed, in the context of intracellular Histoplasma
infection, that the pleiotropic cytokine, granulocyte macrophage-
colony stimulating factor (GM-CSF), is capable of stimulating
macrophages to upregulate expression of zinc exporters, Slc30a4
and Slc30a7, so that the zinc was shuttled away fromphagosomes
and into the Golgi apparatus.[262] This distinctive zinc sequestra-
tion strategy has the effect of elevating phagosomal H+ channel
function and triggering ROS generation by NADPH oxidase.[263]
It is possible that retinal parainflammation might be character-
ized by similarmacrophage effects on zinc homeostasis and ROS
generation.
8. Zinc and the Microbiome
In addition to the direct effects of zinc on innate and adaptive im-
munity described previously, zinc may influence retinal inflam-
mation indirectly via its effects on the microbiome and immune
cells in the gut. It is nowwell recognized that the human immune
system has a highly co-evolved relationship with the microbes
that inhabit the human intestine, resulting in the maintenance
of homeostasis between the host and resident microbes.[264] This
relationshipwith intestinal bacteria, known as themicrobiome, is
shaped during development and into adulthood, and contributes
to the function of the gastrointestinal immune system and play
an important role in health and disease throughout life.[264] Dys-
biosis, “an imbalance in microbiota structure and/or function
that disrupts host microorganism homeostasis,” is an emerging
feature of many non-communicable inflammatory diseases.[265]
If retinal parainflammation develops into a chronic retinal mal-
function, and constitutes a shift in the normal homeostasis or
“balance” to adapt to the new physiological or metabolic condi-
tions of AMD (as occurs in many other chronic inflammatory
disease states), the disruption in the interrelationships between
nutrition, the microbiome, and host metabolism may be key ele-
ments in the disruption of normal homeostasis. The gut micro-
biome composition may vary according to macro/micronutrient
dietary habits, as shown in several studies.[266–271] The redox state
also strongly modulates the gut microbiota.[272–275] Different bac-
terial taxa modulate immune functionality toward a pro or anti-
inflammatory pattern, extensively summarized previously.[276–278]
Thus, the composition of themicrobiota community determines,
in part, the level of resistance to infection and susceptibility to in-
flammatory diseases.
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We propose that nutritional zinc and/or zinc availability in
the intestine might influence systemic inflammation, and con-
sequently, the immune cells driving local retinal inflammation,
through direct interactions with gut microbiota or via effects
on resident T-cells in gut mucosa. Zinc is absorbed mainly in
the stomach, in the small and large intestine via diffusion- and
carrier-mediated mechanism.[279] It is essential for the growth
of most organisms, including numerous bacteria, which require
zinc uptake systems for growth and virulence.[280,281] Studies have
showed that the microbiota have high-affinity binding and trans-
port systems for zinc, and there is zinc competition between mi-
crobiota in the gastrointestinal tract of a host.[280] For example,
it has been shown that excess dietary zinc (Zn) substantially al-
ters the gut microbiota, which in the context of colonization by
pathogenic bacteria, such as Clostridium difficile, may exacerbate
C. difficile–associated disease by increasing toxin activity and al-
tering the host immune response.[282] Regarding factors that may
influence zinc absorption and local zinc availability, it has been
shown that the presence of intestinal mucins facilitates in vitro
zinc uptake into enterocytes and act as a zinc delivery system for
the intestinal epithelium.[282] In a clinical study comparing in-
dividuals with rheumatoid arthritis (RA) with healthy subjects,
the redox environment, transport, and metabolism of iron, sul-
fur, zinc, and arginine were found altered in the microbiota of
individuals with RA, along with detectable specific alterations in
the gut and oralmicrobiome, includingmolecularmimicry of hu-
man antigens related to RA, in individuals with the disease.[283]
These findings suggest that the microbiome composition could
potentially be used as a tool for prognosis and diagnosis of in-
flammation at body sites distant to the gut.
Murine models demonstrate that intestinal RORγ t+FoxP3+
Treg induced in vivo by the local microbiota display a stable sup-
pressive phenotype and exist in dynamic balance with pathogenic
Th17.[284,285] The local microenvironment of the microbiome,
which influences the cytokinemilieu, has been shown to regulate
the Treg/Th17 balance and influence cell plasticity; thus, disrup-
tion of this balancemay lead to the development of inflammatory
disease.[285–287] Since it is known that zinc deficiency may drive
Th17 polarization and promote loss of Treg function,[155] we sug-
gest that interactions between zinc, T-cells, and the microbiome
in the gut may have a role in influencing levels of inflammation
at distant tissue sites, including the retina.
9. Potential Risks of Zinc Supplementation and
Future Directions
Dietary supplements are not subject to the stringent regulation of
pharmaceutical drugs and can be purchased without prescription
in most countries, which has led to concerns over quality, safety,
and potential toxicity of zinc supplements. High dose zinc di-
etary supplementation had been shown to interfere with absorp-
tion of dietary copper and iron,[163] resulting in their deficiency.
In the AREDS trial, zinc oxide was observed to be a gastrointesti-
nal irritant and also a cause of urinary complications,[288] with pa-
tients taking zinc being hospitalizedmore often for genitourinary
complaints.[184] Furthermore, whilst zinc is an important regula-
tor of inflammation and immune function, it can also suppress
the immune system, increasing the risk for certain cancers, in-
cluding metastatic prostate cancer.[2]
The potential safety risks of nutrient supplementation, in ad-
dition to questions about efficacy[289,290] in the context of AMD,
have led to a renewed public health interest and research focus
on components of a healthy balanced diet and dietary patterns,
which provide the necessary required vitamins and micronutri-
ents for optimal visual and body function.[60] In particular, the
Mediterranean dietary pattern appears promising in reducing the
risk of progression of AMD.[291,292] In addition to the focus on
increasing zinc intake through dietary supplementation in zinc
deficient individuals, it is also important to optimize dietary zinc
intake through improving absorption of available dietary zinc, for
example, byminimizing the effect of phytates on zinc absorption.
Finally, it is recognized that in order for the clinical translation of
nutritional science on zinc to progress, valid, reliable, and feasi-
ble biomarkers and surrogate endpoints formeasurement of zinc
status, such as retinal dark adaptation, will need to be developed
for future clinical studies.
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